ROIVANT SCIENCES LTD. Stock-Based Compensation
ROIVANT SCIENCES LTD. (ROIV) reported Stock-Based Compensation of $83.34 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-06
- ROIVANT SCIENCES LTD. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $83.34M, a 1.42% increase year-over-year.
- ROIVANT SCIENCES LTD. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $77.17M, a 7.57% decline year-over-year.
- ROIVANT SCIENCES LTD. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $105.00M, a 25.47% increase year-over-year.
- ROIVANT SCIENCES LTD. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $81.82M, a 14.17% increase year-over-year.
- ROIVANT SCIENCES LTD. share-based payment arrangement, noncash expense for fiscal 2026 was $346.17M, a 19.77% increase from fiscal 2025.
- ROIVANT SCIENCES LTD. share-based payment arrangement, noncash expense for fiscal 2025 was $289.03M, a 44.78% increase from fiscal 2024.
- ROIVANT SCIENCES LTD. share-based payment arrangement, noncash expense for fiscal 2024 was $199.63M, a 8.34% decline from fiscal 2023.
- ROIVANT SCIENCES LTD. share-based payment arrangement, noncash expense for fiscal 2023 was $217.78M, a 61.45% decline from fiscal 2022.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $83.34M 10-Q · filed 2026-08-06 | $160.51M derived: sum of 2 quarters · filed 2026-08-06 | $265.51M derived: sum of 3 quarters · filed 2026-08-06 | $347.33M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $77.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | $182.17M derived: sum of 2 quarters · filed 2026-05-20 | $263.99M derived: sum of 3 quarters · filed 2026-05-20 | $346.17M 10-K · filed 2026-05-20 |
| 2025-12-31 | $105.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-06 | $186.82M derived: sum of 2 quarters · filed 2026-02-06 | $269.00M 10-Q · filed 2026-02-06 | $352.48M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-09-30 | $81.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-10 | $164.00M 10-Q · filed 2025-11-10 | $247.49M derived: sum of 3 quarters · filed 2026-08-06 | $331.17M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $82.18M 10-Q · filed 2026-08-06 | $165.67M derived: sum of 2 quarters · filed 2026-08-06 | $249.35M derived: sum of 3 quarters · filed 2026-08-06 | $321.02M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $83.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | $167.17M derived: sum of 2 quarters · filed 2026-05-20 | $238.84M derived: sum of 3 quarters · filed 2026-05-20 | $289.03M 10-K · filed 2026-05-20 |
| 2024-12-31 | $83.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-06 | $155.35M derived: sum of 2 quarters · filed 2026-02-06 | $205.54M 10-Q · filed 2026-02-06 | $252.26M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-09-30 | $71.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-10 | $121.86M 10-Q · filed 2025-11-10 | $168.58M derived: sum of 3 quarters · filed 2026-05-20 | $222.91M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-06-30 | $50.19M 10-Q · filed 2025-08-11 | $96.92M derived: sum of 2 quarters · filed 2026-05-20 | $151.24M derived: sum of 3 quarters · filed 2026-05-20 | $200.56M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-03-31 | $46.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | $101.05M derived: sum of 2 quarters · filed 2026-05-20 | $150.37M derived: sum of 3 quarters · filed 2026-05-20 | $199.63M 10-K · filed 2026-05-20 |
| 2023-12-31 | $54.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-02-10 | $103.64M derived: sum of 2 quarters · filed 2025-02-10 | $152.90M 10-Q · filed 2025-02-10 | $178.18M derived: sum of 4 quarters · filed 2025-05-29 |
| 2023-09-30 | $49.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-12 | $98.58M 10-Q · filed 2024-11-12 | $123.86M derived: sum of 3 quarters · filed 2025-05-29 | $181.59M derived: sum of 4 quarters · filed 2025-05-29 |
| 2023-06-30 | $49.26M 10-Q · filed 2024-08-09 | $74.54M derived: sum of 2 quarters · filed 2025-05-29 | $132.27M derived: sum of 3 quarters · filed 2025-05-29 | $194.25M derived: sum of 4 quarters · filed 2025-05-29 |
| 2023-03-31 | $25.28M derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-29 | $83.01M derived: sum of 2 quarters · filed 2025-05-29 | $144.99M derived: sum of 3 quarters · filed 2025-05-29 | $217.78M 10-K · filed 2025-05-29 |
| 2022-12-31 | $57.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-02-13 | $119.71M derived: sum of 2 quarters · filed 2024-02-13 | $192.50M 10-Q · filed 2024-02-13 | $269.66M derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-09-30 | $61.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-11-13 | $134.77M 10-Q · filed 2023-11-13 | $211.93M derived: sum of 3 quarters · filed 2023-11-13 | $283.15M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $72.79M 10-Q · filed 2023-08-14 | $149.95M derived: sum of 2 quarters · filed 2023-08-14 | $221.17M derived: sum of 3 quarters · filed 2023-08-14 | $618.48M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $77.16M derived: 10-K 12 month − 10-Q 9 month · filed 2023-06-28 | $148.38M derived: sum of 2 quarters · filed 2023-06-28 | $545.69M derived: sum of 3 quarters · filed 2023-06-28 | $564.96M 10-K · filed 2023-06-28 |
| 2021-12-31 | $71.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-02-13 | $468.53M derived: sum of 2 quarters · filed 2023-02-13 | $487.80M 10-Q · filed 2023-02-13 | $527.24M derived: sum of 4 quarters · filed 2023-02-13 |
| 2021-09-30 | $397.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-11-14 | $416.58M 10-Q · filed 2022-11-14 | $456.02M derived: sum of 3 quarters · filed 2022-11-14 | $473.35M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $19.27M 10-Q · filed 2022-08-15 | $58.71M derived: sum of 2 quarters · filed 2022-08-15 | $76.03M derived: sum of 3 quarters · filed 2022-08-15 | $89.95M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $39.44M derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-28 | $56.77M derived: sum of 2 quarters · filed 2022-06-28 | $70.68M derived: sum of 3 quarters · filed 2022-06-28 | $84.96M 10-K · filed 2022-06-28 |
| 2020-12-31 | $17.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-02-14 | $31.24M derived: sum of 2 quarters · filed 2022-02-14 | $45.52M 10-Q · filed 2022-02-14 | |
| 2020-09-30 | $13.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-11-15 | $28.19M 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | $14.28M 10-Q · filed 2021-09-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |